MITOXANTRONE HYDROCHLORIDE by Hikma is clinical pharmacology: mechanism of action mitoxantrone, a dna-reactive agent that intercalates into deoxyribonucleic acid (dna) through hydrogen bonding, causes crosslinks and strand breaks. Approved for the treatment of patients with primary progressive multiple sclerosis, the initial therapy of acute nonlymphocytic leukemia (anll) in adults. First approved in 2006.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY: Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an…
Worked on MITOXANTRONE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies